Galmed Pharmaceuticals | Evaluate

Investors toast Galmed Nash results, but what will the FDA say?

February 16, 2018

Snippet roundup: Alzheimer’s doubts grow and Bavencio's Javelin falls short

September 13, 2017

Intercept’s safety scare ramps up Nash pressure

February 13, 2017

Intercept strikes at the heart of the Nash problem

September 20, 2016

Allergan sparks a second liver disease craze

May 03, 2016

Therapy focus – NASH projects set for data in dog days of summer

April 27, 2016

Interview – Boehringer’s new look aims to boost innovation

September 24, 2015

Conatus makes a splash in NASH

April 08, 2015

Astra first big pharma to dip toe in simmering NASH waters

March 27, 2015

Behind the management smokescreen, Genfit study is still a fail

March 10, 2015

NASH craze lives on, despite the unknowns

Load More